B of A Securities Downgrades Elevance Health to Neutral, Lowers Price Target to $530
Portfolio Pulse from Benzinga Newsdesk
B of A Securities has downgraded Elevance Health (NYSE:ELV) from Buy to Neutral and lowered the price target from $646 to $530.
July 18, 2024 | 11:09 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
B of A Securities has downgraded Elevance Health from Buy to Neutral and reduced the price target from $646 to $530, indicating a less optimistic outlook.
The downgrade from Buy to Neutral and the significant reduction in the price target suggest that B of A Securities has a less optimistic view on Elevance Health's future performance. This is likely to negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100